Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shults, C. W.
Right arrow Articles by Haas, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shults, C. W.
Right arrow Articles by Haas, R. H.
NEUROLOGY 1998;50:793-795
© 1998 American Academy of Neurology

Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients

C. W. Shults, MD, M. Flint Beal, MD, D. Fontaine, K. Nakano, MD and R. H. Haas, MD

From the Department of Neurosciences (Drs. Shults, Nakano, and Haas and D. Fontaine), University of California, San Diego, La Jolla, CA; Neurology Service (Dr. Shults), VA Healthcare System, San Diego; and Massachusetts General Hospital (Dr. Beal), Boston, MA.

Address correspondence and reprint requests to Dr. Clifford W. Shults, VA Medical Center (127), 3350 La Jolla Village Drive, San Diego, CA 92161.

We report a pilot study of three oral doses of coenzyme Q10(CoQ10) (200 mg administered two, three, or four times per day for 1 month) in 15 subjects with Parkinson's disease. Oral CoQ10 caused a substantial increase in the plasma CoQ10 level. It was well tolerated, but at the highest dose (200 mg four times per day) mild, transient changes in the urine were noted. CoQ10 did not change the mean score on the motor portion of the Unified Parkinson's Disease Rating Scale. There was a trend toward an increase in complex I activity in the subjects.

Supported by a Center of Excellence Award from the National Parkinson Foundation to C.S. and grants NS32365 and PO1 AG12992 to M.F.B.

Received May 8, 1997. Accepted in final form September 9, 1997.




This article has been cited by other articles:


Home page
 NeurologyHome page
P. S. Sandor, L. Di Clemente, G. Coppola, U. Saenger, A. Fumal, D. Magis, L. Seidel, R. M. Agosti, and J. Schoenen
Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial
Neurology, February 22, 2005; 64(4): 713 - 715.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. L. Horvath, S. Diano, C. Leranth, L. M. Garcia-Segura, M. A. Cowley, M. Shanabrough, J. D. Elsworth, P. Sotonyi, R. H. Roth, E. H. Dietrich, et al.
Coenzyme Q Induces Nigral Mitochondrial Uncoupling and Prevents Dopamine Cell Loss in a Primate Model of Parkinson's Disease
Endocrinology, July 1, 2003; 144(7): 2757 - 2760.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
B.M. Ravina, S.C. Fagan, R.G. Hart, C.A. Hovinga, D.D. Murphy, T.M. Dawson, and J.R. Marler
Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment
Neurology, April 22, 2003; 60(8): 1234 - 1240.
[Abstract] [Full Text] [PDF]

Home page
 Sci Aging Knowl EnvironHome page
O. Ogawa, X. Zhu, G. Perry, and M. A. Smith
Mitochondrial Abnormalities and Oxidative Imbalance in Neurodegenerative Disease
Sci. Aging Knowl. Environ., October 16, 2002; 2002(41): pe16 - 16.
[Abstract] [Full Text]

Home page
 Arch NeurolHome page
C. W. Shults, D. Oakes, K. Kieburtz, M. F. Beal, R. Haas, S. Plumb, J. L. Juncos, J. Nutt, I. Shoulson, J. Carter, et al.
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Arch Neurol, October 1, 2002; 59(10): 1541 - 1550.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Santos-Ocana, T. Q. Do, S. Padilla, P. Navas, and C. F. Clarke
Uptake of Exogenous Coenzyme Q and Transport to Mitochondria Is Required for bc1 Complex Stability in Yeast coq Mutants
J. Biol. Chem., March 22, 2002; 277(13): 10973 - 10981.
[Abstract] [Full Text] [PDF]

Home page
 Sci Aging Knowl EnvironHome page
J. K. Andersen, J. Kumar, B. Srinivas, D. Kaur, M. Hsu, and S. Rajagopalan
The Hunt for a Cure for Parkinson's Disease
Sci. Aging Knowl. Environ., October 3, 2001; 2001(1): re1 - 1.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
J. Jankovic
New and Emerging Therapies for Parkinson Disease
Arch Neurol, July 1, 1999; 56(7): 785 - 790.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by AAN Enterprises, Inc.